SCHEMBL7923072

SCHEMBL7923072

Cc1cc2c(cn1)N(C)CC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
PKM P14618 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
THPO P40225 1/20 0.39
RAB9A P51151 1/20 0.39
HIF1A Q16665 1/20 0.39
MAPT P10636 2/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GRM5 P41594 1/20 0.36
NOTUM Q6P988 3/20 0.36
WDR5 P61964 1/20 0.36
PDE10A Q9Y233 1/20 0.36
CHRNA7 P36544 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7926276 0.85 GRM5 (0.36) NPC1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL25044274 0.79 GRM5 (0.36) NPC1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL22583106 0.77 GRM5 (0.37) NPC1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL23975571 0.77 CHRNB2 (0.41) TP53CYP3A4CYP2D6TSHRMAPT
SCHEMBL29435537 0.77 GRM5 (0.37) NPC1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL2669112 0.75 MEN1 (0.51) GRM5LRRK2MEN1KMT2AHTR2A
SCHEMBL16664382 0.74 ALDH1A1 (0.41) MAPTWDR5MEN1ALDH1A1GAA
SCHEMBL23349376 0.74 PDE10A (0.35) NPC1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL29435624 0.73 NPC1 (0.34) NPC1TP53CYP1A2CYP3A4CYP2D6
SCHEMBL22582941 0.73 NPC1 (0.34) NPC1TP53CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB NPC1 978/4885TP53 2273/4885CYP1A2 2432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.